No Data
Biokin Pharmaceutical Gets Nod to Trial Solid Tumor Drug
Bailihengteng (688506.SH): The injection of BL-M07D1 (HER2-ADC) for postoperative adjuvant treatment of HER2-positive breast cancer with residual invasive carcinoma after neoadjuvant therapy has obtained approval for a Phase III clinical trial.
On February 7, GELONGHUI reported that Baile Tianheng (688506.SH) announced that it has recently received the "Drug Clinical Trial Approval Notice" officially approved and issued by the National Medical Products Administration (NMPA). The company's self-developed innovative biological drug injectable BL-M07D1 (HER2-ADC) has obtained approval for its Phase III clinical trial. BL-M07D1 is an innovative ADC targeting HER2, with best-in-class potential, and has shown significant anti-tumor efficacy in clinical trials.
Baili Tianheng (688506.SH): Re-submitted the application for the issuance and listing of Overseas Listed Foreign Shares (Listed in Hong Kong) to the Hong Kong Stock Exchange.
Baili Tianheng (688506.SH) announced that the company is applying for an Overseas public offering of Stocks (H shares) and will be listed in Hong Kong...
New stock news | Baili Tianheng (688506.SH) re-submitted to the Hong Kong Stock Exchange, with a profit of 4.065 billion yuan in the first three quarters of 2024.
Baili Tianheng is a comprehensive pharmaceutical group that operates two main Business: innovative biopharmaceutical Business and generic drugs and Chinese Patent Medicine Business.
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 annual results forecast
